ArticleIn vivo (Athens, Greece)
Significance of Irisin (FNDC5) Expression in Colorectal Cancer.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Implication of Irisin in Different Types of Cancer: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2022Pooled it
- Myokines in cancer: bridging molecular mechanisms to biomarker discovery and therapeutic innovation.Frontiers in oncology · 2026Review
- Exploring irisin levels in patients with endometrial atypical hyperplasia and carcinoma: a comparative analysis.BMC cancer · 2025Article
- Diagnostic and Therapeutic Value of the Exercise-Induced Myokine Irisin in Cancer Biology: A Comprehensive Review.Diseases (Basel, Switzerland) · 2025Review
- FNDC5 and ACOX1 as Biomarkers of Peroxisomal Activity with Contrast Outcomes in Colon Adenocarcinoma.Biological procedures online · 2025Article
- The Role of the Myokine Irisin in the Protection and Carcinogenesis of the Gastrointestinal Tract.Antioxidants (Basel, Switzerland) · 2024Review
- The Role of Irisin/FNDC5 Expression and Its Serum Level in Breast Cancer.International journal of molecular sciences · 2023Article
- FNDC5 and AKR1B10 inhibit the proliferation and metastasis of adrenocortical carcinoma cells by regulating AMPK/mTOR pathway.Experimental and therapeutic medicine · 2023Article
- Association of Irisin/FNDC5 with ERRα and PGC-1α Expression in NSCLC.International journal of molecular sciences · 2022Article
- Expression of Irisin/FNDC5 in Breast Cancer.International journal of molecular sciences · 2022Article
- The Role of Irisin and Physical Activity in Breast Cancer.In vivo (Athens, Greece)Review
- Irisin Potentiates 5-fluorouracil Cytotoxicity in HT-29 Colon Cancer Cells through Enhanced Apoptosis and Transcriptional Modulation of Adenosine Monophosphate-activated Protein Kinase/Mammalian Target of Rapamycin Signaling.International journal of applied & basic medical researchArticle
- The Effect of Hypoxia on Irisin Expression in HL-1 Cardiomyocytes.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThe role of irisin, the extracellular part of fibronectin type III domain containing 5 (FNDC5), in colorectal cancer (CRC) is unclear. The aim of this study was to investigate immunohistochemical (IHC) expression level of irisin and correlations with clinicopathological factors in patients with CRC. MATERIALS AND
methodsWe collected 222 archived CRC samples and 26 control samples from autopsies conducted at the Department of Forensic Medicine. They were used to perform IHC reactions detecting irisin, Ki-67, minichromosome maintenance protein complex component 3 (MCM3), and urine diphosphate-galactose ceramide galactosyltransferase (UGT3) expression. The correlations with Ki-67, MCM3, and UGT3 were analyzed. Irisin expression was also evaluated in cancer cell lines by immunofluorescence reaction and western blot.
resultsIrisin expression was higher in cancer cells compared to the control tissues (p<0.0001). Irisin expression was significantly higher in stage I than in stage III (p=0.013) and IV CRC (p=0.05).
conclusionThe correlation between higher expression of irisin and cancer stages indicates its potential usefulness as a marker in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.